The ability of several homologous
embryonic chick spinal cord (Farb et al., 1979; Choi et al., 1981 b; Rando et al., 1981) . The GABA receptor is a complex receptor containing a benzodiazepine-binding site/receptor as an integral component. This is consistent with the hypothesis that the antianxiety, muscle-relaxing, and anticonvulsant actions of benzodiazepine agonists are mediated through the GABA receptor complex. Benzodiazepine tranquilizers potentiate GABA action in neuronal chick spinal cord cultures (Choi et al., 1977; Chan et al., 1983) and in vivo (Gallager, 1978; Schlosser and France, 1979) . The discovery of drugs that appear to distinguish between multiple classes of benzodiazepine-binding sites and exhibit varied pharmacological effects raises questions of whether such ligands act through multiple receptor subtypes or with different efficacies through a single benzodiazepine receptor (BZD-R). For example, the triazolopyridazine drug, CL 218,872, binds with high affinity to at least one subset of benzodiazepine sites and, in keeping with this selectivity, is reportedly an effective tranquilizer with relatively few side effects (Klepner et al., 1979; Lippa et al., 1979) . In contrast, the imidazobenzodiazepine, Ro 15-l 788, antagonizes the binding and physiological effects of benzodiazepines (Hunkeler et al., 1981) . Remarkably, certain pcarbolines exert novel effects on the CNS, opposing the actions of benzodiazepines while producing anxiety and convulsant activity in the intact CNS (M6hler and Richards, 1981; Braestrup et al., 1982; Ninan et al., 1982) . Do the P-carboline drugs, methyl-P-carboline-3-carboxylate (P-CCM) and methyl-6,7-dimethoxy-4-ethyl-P-carboline-3-carboxylate (DMCM) , that produce such dramatic pharmacological effects act independently as agonists or as antagonists?
Direct electrophysiological measurement of the actions of BZD-R ligands are needed to determine whether differences in the pharmacological effects of such drugs are due to differential effects upon multiple classes of BZD-Rs or to different efficacies at BZDRs. Described here are some properties of BZD-R ligands as potentiators and inhibitors of GABA-induced conductance increases. Preliminary accounts of these results have been presented (Chan et al., 1982; Farb et al., 1984) .
Materials and Methods
Benzodiazepines were a gift of Dr. W. Scott of F. Hoffman-La Roche (Nutley, NJ). P-CCM and DMCM were a gift of Dr. Claus Braestrup of A/S Ferrosan (Soeborg, Denmark), and CL 218,872 was a gift of Lederle Laboratones (Pearl River, NY). All other chemicals were obtained from commercial sources. Neurons were dissociated from spinal cords of 7-day chick embryos, plated on collagen-coated 35mm plastic tissue culture dishes (plating density 4 x lo5 cells/dish), and malntained In culture for 2 to 6 weeks as previously described (Farb et al., 1979; Choi et al., 1981a The perfusion medium surrounding the target neuron is effectively replaced during pressure ejection (Choi et al., 198la) . The conductance change due to GABA application ( gGABA) is calculated as the observed conductance in the presence of GABA (gobs) minus the membrane conductance at rest: g GABA = g&, -g,,,.
[GABA] (2 to 5 brn) was used to give gGABA = 1 to 6 nS for potentiators, whereas higher [GABA] (17 PM; gGAL = 50 to 70 nS) was used with inhibitors to increase the precision of measurement.
The degree of inhibition bv B-CCM or DMCM is not a function of [GABA] (see '??esults"), unlike potentiation which decreases at high GABA (see Fig. 5 ). The percentage of potentiation or inhibition of the GABA response (a or -a) is given by the equation LY = [( gGABA'/gGABA) -1] x 100, where gGABA' is determined after drug application. Values of LY or gGABA'/gGABA are, respectrvely, >O or >l for potentiators; 0 or 1 for conditions wrthout effect; and <O or <l for inhibitors of gGABA. In the presentatron of results and discussion below, LY is generally used when it IS more informative to use percentages for expression of data. For each neuron, the ECso and ( gGABA'/gGABJmax were estimated by weighted Eadie-Hofstee analysis and by nonlinear regression.
Water-insoluble drugs were dissolved in dimethyl sulfoxide and diluted to a final concentration of 0.2% dimethyl sulfoxide that did not alter g, or gGABA.
Results fl-CCM and DMCM inhibit GABA-induced conductance increases. Figure  1 shows that DMCM (100 nM) and P-CCM (1 PM) reduced the GABA (17 PM) response. When applied alone, P-CCM did not exhibit direct effects on input resistance or resting potential. Inhibition of gGABA depended on ligand concentration, was saturable, and obeyed Michaelis-Menten kinetics (Hill slope 1). The results are consistent with a specific, single class of functional pcarboline sites (/I-CCM: ECso = 18 nM, O(,,,~ = -55%; DMCM: ECSo = IO nM; amax = -66%; see Fig. 2 ). Ro 75-1788 and CL 278,872 are partial agonists.
Surpnsingly, whereas Ro 15-l 788 is an antagonist of benzodiazepine action in viva, it potentiated gcnsn (Table I) . However, Ro 15-l 788 displayed a low efficacy (amax = 72%) and high potency (EC& = 0.13 WM) as compared with diazepam (EC-= 0.57 PM; ama = 453%) (Table I, Figs. 2 and 3) in keeping with its actions as an antagonist of the pharmacological actions of classical benzodiazepines (Hunkeler et al., 1981; Bonetti et al., 1982 : Darraah et al., 1982 (Ro 15-1788) and (3) parka1 efficacy of inhibition with very high potency (P-CCM and DMCM). A good correlation (Fig. 3) was observed between the efficacy ( gGABA'/gGABA) -for potentiation or inhibition of gGABA and the GABA ratios determined in binding assays (Braestrup et al., 1982) . The GABA ratio, {IC, for competing ligand In the presence of muscimol}/ {I& in the absence of muscimol], reflects the efficacy of enhancement by GABA agonists of modulator ligand brndrng to membrane homogenates at 0°C. The fact that a good correlation was found supports the hypothesis that the benzodiazepine and nonbenzodiazepine ligands that modulate gmB wrth positive and negative efficacy act through a common receptor mechanism.
Puotoxin and fl-CCM inhibit gcasa through different sites. Would prcrotoxin, itself a noncompetitive inhibitor of GABA action, block inhibition of gcmsn by P-CCM? fl-CCM inhibited g GABA (at 100 PM GABA) to the same extent in the presence or absence of picrotoxin (30 to 100 PM) (Fig. 4 ) indicatinq the independence of the two inhibitory mechanisms and arqurnq that P-CCM and picrotoxin act at different sites. Picrotoxin was abie to completelv inhibit aRnnn (at 100 UM GABA: 01 = -92 f 2%. n = 11, at 30 UM picrdtoxrnj and CY i--98 + 1% n = 3 at 70 FM picrotoxin), unlike P-&M and DMCM which exhibited saturable and partial inhrbition.
GABA does not surmount the inhibition of gcnen by @-CCM or DMCM. p-CCM inhibited gcnsA to about the same extent at all of the GABA concentrations tested (see Fig. 5 ). A saturating concentration of P-CCM (1 PM; EC& = 0.018 PM) reduced g,,,
by 53 -C 9% at 17 PM GABA (n = 4), by 50 + 5% at 100 pM GABA (n = 6) and by 46% at 500 NM GABA (n = 2). When a complete experiment was carried out on a single neuron, 1 PM fi-CCM inhibited the responses to 17 WM and 100 PM GABA identically, to within error (Student's t test, p > 0.2). Similarly, GABA did not surmount the inhibition of gGABA by DMCM: maximal inhibition of g,,,, was 68 f 6% (n = 4) (DMCM. 500 nM: GABA. 17 UM). Usina 30 nM DMCM (subsaturatinal. the decrease in gcnsn was 55% (n'= 2) at 5'0 PM GABA, and 40 + 5% (n'= 7) at 200 PM GABA. Thus, the activities of fi-CCM and DMCM were apparently insurmountable by GABA, suggesting that both P-carbolines are either partial noncompetitive or uncompetitive inhibitors of gcnsA. GABA surmounts benzodiazepine potentiation of gGABA. Figure 5 shows that increasing [GABA] decreased (Y for chlordiazepoxide, as expected since chlordiazepoxide decreases the GABA ECso from 17 PM to 8 PM with no change in ( gcns, Jmax (Choi et al., 198la) . Similar results were observed with other benzodiazepines:
at 2 FM and 100 I.LM GABA the arna*for flunitrazepam was, respectively, 516% and 48%; similarly, the amax for clonazepam was 348% -C 10 (n = 5) at 2 to 5 FM GABA and undetectable (-O%, n = 2) at 200 PM GABA. In contrast, GABA did not surmount the activity of P-carbolines (see above The relative inhibition of gat 17 ELM and 100 +! GABA by P-CCM (1 PM) was not reduced by 30 or 85 PM picrotoxin.
Note that each bar of the graph has been normalized to correct for inhibition of gproduced by picrotoxin itself. Actual gGABA responses in the presence of 85 PM picrotoxin were about 10% of those observed in the absence of picrotoxin; thus, picrotoxin decreases g,, but does not diminish the action of P-CCM. conductance. In the classical model of drug-receptor interaction, as develUntil recently, the possibility of negative efficacy has remained a matheoped by Clark (1933 ), Gaddum (1937 ), and Stephenson (1956 , the magnimatlcal curiosity. In general, the receptors whrch have been extensively tude of the observed response was hypothesized to be a function, f(S), of studied exhibit little actrvity in the absence of agonist. This is not surprising the stimulus S produced by occupancy of receptor, which is inactive at rest, for receptors such as the acetylcholine or GABA receptors which are directly by agonist (A) as the consequence of a simple binding equilibrium. Thus, linked to ion channels. However, the neuromodulators that act through BZDresponse = f(S) and S = e x {[A]/ ([A] + &)J, where the efficacy factor, e, Rs do not by themselves produce a physiological response ( Fig. 113 and is an empirical constant that relates the maximal response obtained to Choi et al., 1981a) , but control the sensitivity of the GABA receptor to its receptor occupancy, and Kdis the equilibrium dissociation constant for ligand transmitter, GABA. In this system a combination of negative and positive binding. Efficacy is generally assumed to be positive: however, if some modulation might prove advantageous, and many of the effects of benzodireceptor activity IS present in the absence of agonist, it is theoretically azepines and related compounds (e.g., P-carbolines and triazolopyridazines) possible for a drug to display negative efficacy by reducing the response are explicable with such a model. For example, clinically effective benzodibelow the resting level.
azepine anxiolytics promote g,,,, (Table I) and bind with higher affinity in (Fig. 2) Figure 3 provide the first evidence supporting the idea that the Dodd, P. Potter, J. Rossier, and G. Chapouthier (1983) Distinct behavroral ability of GABA to enhance/inhibit ligand binding to the benzodiazeprneand pharmacological effects of two benzodiazepine antagonists: Ro 15. bindrng site (7 ) is a valid measure of the ability of such ligands to modulate 1788 and methyl P-carboline. Adv. Biochem. Psychopharmacol. 38: 175-gGABA, and (2) may be taken as an indicator of agonist/antagonist efficacy. 187.
